These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 14559126)

  • 41. The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction.
    Sabatine MS; Antman EM
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):89S-95S. PubMed ID: 12644346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
    Huynh T; Piazza N; DiBattiste PM; Snapinn SM; Wan Y; Pharand C; Theroux P
    Int J Cardiol; 2005 Apr; 100(1):73-8. PubMed ID: 15820288
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
    N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).
    Gibson CM; Singh KP; Murphy SA; DiBattiste PM; Demopoulos LA; Cannon CP; Braunwald E;
    Am J Cardiol; 2004 Aug; 94(4):492-4. PubMed ID: 15325937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
    Circulation; 1998 Jun; 97(24):2386-95. PubMed ID: 9641689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
    Tcheng JE
    Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231
    [No Abstract]   [Full Text] [Related]  

  • 49. New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction.
    O'Rourke RA; Hochman JS; Cohen MC; Lucore CL; Popma JJ; Cannon CP
    Arch Intern Med; 2001 Mar; 161(5):674-82. PubMed ID: 11231699
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of coronary revascularization in patients with unstable and non-ST-segment elevation acute myocardial infarction.
    Popma JJ; Suk J
    Am J Cardiol; 2001 Oct; 88(8A):25K-29K. PubMed ID: 11694216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
    Tatlisu MA; Kaya A; Keskin M; Uzman O; Borklu EB; Cinier G; Hayiroglu MI; Eren M
    Coron Artery Dis; 2016 Nov; 27(7):543-50. PubMed ID: 27341666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
    Circulation; 1997 Sep; 96(5):1445-53. PubMed ID: 9315530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome.
    Song Y
    J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):142-4. PubMed ID: 17497280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris.
    Sabatine MS; Januzzi JL; Snapinn S; Théroux P; Jang IK
    Am J Cardiol; 2001 Sep; 88(5):488-92. PubMed ID: 11524055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
    Boersma E
    J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy of low-molecular-weight heparin in acute coronary syndromes.
    Wallentin L
    Am Heart J; 2000 Feb; 139(2 Pt 2):S29-32. PubMed ID: 10650313
    [No Abstract]   [Full Text] [Related]  

  • 58. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ
    Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
    Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
    Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.